NYSE:HSP - Hospira Stock Price, Price Target & More

$89.96 0.00 (0.00 %)
(As of 04/25/2018 04:00 PM ET)
Previous Close$89.96
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market Capitalization$15.56 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Hospira (NYSE:HSP)

Hospira logoHospira, Inc. provides injectable pharmaceutical drugs and infusion technologies and it develops, manufactures, distributes and markets biosimilars. The Company's portfolio includes generic acute-care and oncology injectables, biosimilars, and integrated infusion therapy and medication management products. The Company conducts operations across the world and is managed in three segments: the Americas, which include the United States, Canada, and Latin America; Europe, Middle East, and Africa (EMEA), and the Asia Pacific, which includes Asia, Japan, Australia and New Zealand. Its portfolio of products includes Specialty Injectable Pharmaceuticals, which includes generic injectables, injectables and biosimilars, Medication Management and Other Pharmaceuticals. Its portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities.

Receive HSP News and Ratings via Email

Sign-up to receive the latest news and ratings for HSP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
SymbolNYSE:HSP
CUSIP44106010
Phone+1-847-9376472

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins12.15%
Return on Equity16.51%
Return on Assets8.65%

Miscellaneous

EmployeesN/A
Outstanding SharesN/A

How to Become a New Pot Stock Millionaire

Hospira (NYSE:HSP) Frequently Asked Questions

What is Hospira's stock symbol?

Hospira trades on the New York Stock Exchange (NYSE) under the ticker symbol "HSP."

How were Hospira's earnings last quarter?

Hospira, Inc. (NYSE:HSP) announced its quarterly earnings results on Wednesday, July, 29th. The healthcare company reported $0.85 EPS for the quarter, topping analysts' consensus estimates of $0.78 by $0.07. The healthcare company earned $1.20 billion during the quarter, compared to analyst estimates of $1.18 billion. Hospira had a return on equity of 16.51% and a net margin of 12.15%. The firm's revenue was up 4.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.72 earnings per share. View Hospira's Earnings History.

Has Hospira been receiving favorable news coverage?

Headlines about HSP stock have trended somewhat positive on Wednesday, according to Accern Sentiment. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Hospira earned a daily sentiment score of 0.12 on Accern's scale. They also gave news articles about the healthcare company an impact score of 45.29 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of Hospira?

Shares of HSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Hospira's stock price today?

One share of HSP stock can currently be purchased for approximately $89.96.

How big of a company is Hospira?

Hospira has a market capitalization of $15.56 billion.

How can I contact Hospira?

Hospira's mailing address is 275 N Field Dr, LAKE FOREST, IL 60045-2579, United States. The healthcare company can be reached via phone at +1-847-9376472.


MarketBeat Community Rating for Hospira (HSP)

Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  106 (Vote Outperform)
Underperform Votes:  212 (Vote Underperform)
Total Votes:  318
MarketBeat's community ratings are surveys of what our community members think about Hospira and other stocks. Vote "Outperform" if you believe HSP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HSP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Hospira (NYSE:HSP) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 4/25/2016 forward)

Earnings

Hospira (NYSE:HSP) Earnings History and Estimates Chart

Earnings by Quarter for Hospira (NYSE:HSP)

Hospira (NYSE HSP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/29/2015Q215$0.78$0.85$1.18 billion$1.20 billionViewN/AView Earnings Details
4/28/2015Q115$0.51$0.97$1.08 billion$1.18 billionViewN/AView Earnings Details
2/12/2015Q414$0.41$0.53$1.12 billion$1.13 billionViewListenView Earnings Details
11/6/2014Q314$0.53$0.74$1.08 million$1.15 billionViewListenView Earnings Details
7/30/2014Q214$0.56$0.72$1.05 billion$1.14 billionViewListenView Earnings Details
4/30/2014Q114$0.49$0.60$1.02 billion$1.10 billionViewListenView Earnings Details
2/12/2014Q413$0.50$0.51$1.06 billion$1.10 billionViewListenView Earnings Details
11/6/2013Q3 2013$0.45$0.51$993.94 million$1.0082 billionViewN/AView Earnings Details
7/31/2013Q2 2013$0.51$0.55$1.03 billion$1.03 billionViewListenView Earnings Details
5/1/2013Q1 2013$0.44$0.52$979.33 million$884.00 millionViewListenView Earnings Details
2/13/2013Q4 2012$0.54$0.55$1.04 billion$1.10 billionViewListenView Earnings Details
11/7/2012Q312$0.45$0.47$987.67 million$994.00 millionViewN/AView Earnings Details
8/1/2012$0.49$0.51ViewN/AView Earnings Details
5/1/2012$0.46$0.47ViewN/AView Earnings Details
2/14/2012$0.47$0.51ViewN/AView Earnings Details
10/26/2011$0.95$0.66ViewN/AView Earnings Details
7/27/2011$0.79$0.94ViewN/AView Earnings Details
4/26/2011$0.78$0.93ViewN/AView Earnings Details
2/2/2011$0.93$0.77ViewN/AView Earnings Details
10/26/2010Q3 2010$0.69$0.74ViewN/AView Earnings Details
7/28/2010Q2 2010$0.79$0.86ViewN/AView Earnings Details
4/27/2010Q1 2010$0.72$0.94ViewN/AView Earnings Details
2/4/2010Q4 2009$0.70$0.87ViewN/AView Earnings Details
10/27/2009Q3 2009$0.68$0.90ViewN/AView Earnings Details
7/29/2009Q2 2009$0.60$0.73ViewN/AView Earnings Details
4/28/2009Q1 2009$0.54$0.60ViewN/AView Earnings Details
2/17/2009Q4 2008$0.76$0.78ViewN/AView Earnings Details
11/5/2008Q3 2008$0.63$0.63ViewN/AView Earnings Details
8/6/2008Q2 2008$0.62$0.57ViewN/AView Earnings Details
5/7/2008Q1 2008$0.54$0.55ViewN/AView Earnings Details
2/28/2008Q4 2007$0.57$0.63ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Hospira (NYSE:HSP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Hospira (NYSE HSP) Insider Trading and Institutional Ownership History

Insider Trading History for Hospira (NYSE:HSP)

Hospira (NYSE HSP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/2/2015Matthew R StoberSVPSell21,833$87.49$1,910,169.17View SEC Filing  
2/27/2015Matthew R StoberSVPSell25,338$87.47$2,216,314.86View SEC Filing  
2/17/2015Thomas E WernerCFOSell1,566$87.35$136,790.10View SEC Filing  
1/15/2015Thomas E WernerCFOSell10,000$61.56$615,600.00View SEC Filing  
1/12/2015Matthew R StoberSVPSell2,000$61.80$123,600.00View SEC Filing  
12/15/2014Thomas E WernerCFOSell10,000$60.86$608,600.00View SEC Filing  
12/2/2014Richard J HoffmanCAOSell21,850$60.32$1,317,992.00View SEC Filing  
11/25/2014Marc J YoskowitzSVPSell11,523$59.93$690,573.39View SEC Filing  
11/24/2014Kenneth F MeyersSVPSell46,250$59.66$2,759,275.00View SEC Filing  
11/17/2014Thomas E WernerCFOSell10,000$57.73$577,300.00View SEC Filing  
9/15/2014Thomas E WernerCFOSell10,000$52.74$527,400.00View SEC Filing  
8/15/2014Thomas E WernerCFOSell10,000$55.13$551,300.00View SEC Filing  
7/15/2014Thomas E WernerCFOSell10,000$51.50$515,000.00View SEC Filing  
6/16/2014Thomas E WernerCFOSell10,000$50.82$508,200.00View SEC Filing  
5/21/2014Thomas WernerCFOSell30,000$47.98$1,439,400.0054,614View SEC Filing  
5/16/2014Connie CurranDirectorSell2,000$47.44$94,880.0046,390View SEC Filing  
5/14/2014Barbara BowlesDirectorSell2,000$47.77$95,540.0026,219View SEC Filing  
5/13/2014Richard HoffmanCAOSell15,000$48.07$721,050.0029,440View SEC Filing  
5/12/2014Brian SmithSVPSell40,000$48.00$1,920,000.0052,635View SEC Filing  
3/14/2014Matthew StoberSVPSell19,217$42.28$812,494.7657,363View SEC Filing  
2/26/2014Thomas WernerCFOSell20,000$42.53$850,600.0042,785View SEC Filing  
9/11/2013Richard J HoffmanCAOSell9,850$39.38$387,893.00View SEC Filing  
8/16/2013Matthew StoberSVPSell4,990$40.12$200,198.8048,619View SEC Filing  
6/7/2013Sumant RamachandraSVPSell23,702$35.69$845,924.38View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Hospira (NYSE HSP) News Headlines

Source:
DateHeadline
10 Best S&P 500 Health Care Stocks10 Best S&P 500 Health Care Stocks
www.thestreet.com - April 7 at 9:44 AM
Analyzing Hospira (HSP) and The Medicines (MDCO)Analyzing Hospira (HSP) and The Medicines (MDCO)
www.americanbankingnews.com - January 22 at 11:32 AM
Head-To-Head Contrast: The Medicines (MDCO) and Hospira (HSP)Head-To-Head Contrast: The Medicines (MDCO) and Hospira (HSP)
www.americanbankingnews.com - January 20 at 3:16 AM
Head to Head Analysis: Hospira (HSP) & Cumberland Pharmaceuticals (CPIX)Head to Head Analysis: Hospira (HSP) & Cumberland Pharmaceuticals (CPIX)
www.americanbankingnews.com - January 18 at 11:32 PM
Hospira (HSP) & The Medicines (MDCO) Critical AnalysisHospira (HSP) & The Medicines (MDCO) Critical Analysis
www.americanbankingnews.com - December 26 at 4:39 PM
Analyzing Depomed (DEPO) & Hospira (NYSE:HSP)Analyzing Depomed (DEPO) & Hospira (NYSE:HSP)
www.americanbankingnews.com - July 24 at 11:20 AM
Contrasting Hospira (NYSE:HSP) and Depomed (DEPO)Contrasting Hospira (NYSE:HSP) and Depomed (DEPO)
www.americanbankingnews.com - July 22 at 7:12 PM
Canada’s Cannabis Boom Creating a $30 Billion Investment OpportunityCanada’s Cannabis Boom Creating a $30 Billion Investment Opportunity
www.baystreet.ca - April 20 at 11:45 AM
Retrophin Appoints Ron Squarer to Board of DirectorsRetrophin Appoints Ron Squarer to Board of Directors
feeds.benzinga.com - April 12 at 5:49 PM
ICU Medical Wins Big Price Cut to Buy Pfizers Hospira UnitICU Medical Wins Big Price Cut to Buy Pfizer's Hospira Unit
www.thestreet.com - January 6 at 6:23 PM
Highest paid Phoenix doctors by pharma and medical device makersHighest paid Phoenix doctors by pharma and medical device makers
www.bizjournals.com - December 5 at 11:01 AM
Pfizer: A Pharmaceutical Company In TransitionPfizer: A Pharmaceutical Company In Transition
seekingalpha.com - November 3 at 5:23 PM
[$$] ICU Medical To Buy Pfizer Unit in $1 Billion Deal[$$] ICU Medical To Buy Pfizer Unit in $1 Billion Deal
www.wsj.com - October 6 at 10:49 AM
As opioid epidemic grows, so do prices of lifesaving overdose drugsAs opioid epidemic grows, so do prices of lifesaving overdose drugs
www.cnbc.com - September 23 at 5:09 PM
Pfizer earnings rise, boosted by Hospira assets - Yahoo Finance UKPfizer earnings rise, boosted by Hospira assets - Yahoo Finance UK
uk.finance.yahoo.com - May 4 at 2:11 AM
Pfizer earnings rise, boosted by Hospira assetsPfizer earnings rise, boosted by Hospira assets
uk.finance.yahoo.com - May 3 at 8:33 AM
Pfizer: 30%+ Discount With 4% Yield - Seeking AlphaPfizer: 30%+ Discount With 4% Yield - Seeking Alpha
seekingalpha.com - March 22 at 2:32 PM
The Endless GAAP Vs. Non-GAAP Debate: Instead Focus On Cash Flow - Seeking AlphaThe Endless GAAP Vs. Non-GAAP Debate: Instead Focus On Cash Flow - Seeking Alpha
seekingalpha.com - March 17 at 10:52 AM
Hospira Announces U.S. Launch of Generic Bivalirudin for InjectionHospira Announces U.S. Launch of Generic Bivalirudin for Injection
www.prnewswire.com - February 27 at 12:24 PM
Hospira and Cerner Expand Agreement to Advance Integration of I.V.-EMR TechnologyHospira and Cerner Expand Agreement to Advance Integration of I.V.-EMR Technology
www.prnewswire.com - February 25 at 11:38 PM
Pfizer earnings fall on strong dollar, higher expensesPfizer earnings fall on strong dollar, higher expenses
uk.finance.yahoo.com - February 2 at 10:50 AM
Novartis profits jump 73% on asset salesNovartis profits jump 73% on asset sales
uk.finance.yahoo.com - January 27 at 12:02 PM
What Pfizer-Allergan means for manufacturing plant in Rocky MountWhat Pfizer-Allergan means for manufacturing plant in Rocky Mount
www.bizjournals.com - November 23 at 12:55 PM
Pfizer, Allergan weigh blockbuster merger: reportsPfizer, Allergan weigh blockbuster merger: reports
uk.finance.yahoo.com - October 29 at 4:54 AM
Pfizer Inc. -- Moodys assigns A1 to Pfizers proposed exchange notesPfizer Inc. -- Moody's assigns A1 to Pfizer's proposed exchange notes
www.moodys.com - September 3 at 6:05 PM
Ex-Hospira CEO Trades Shares for $91 Million Cash in Pfizer DealEx-Hospira CEO Trades Shares for $91 Million Cash in Pfizer Deal
www.bloomberg.com - September 3 at 4:33 PM
HOSPIRA INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisition or DispositHOSPIRA INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposit
biz.yahoo.com - September 3 at 12:38 PM

SEC Filings

Hospira (NYSE:HSP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Hospira (NYSE:HSP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Hospira (NYSE HSP) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.